Drug Information
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides eggerthii
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Imatinib can be metabolized by Bacteroides eggerthii. | |||
|
Studied Microbe: Bacteroides stercoris
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Imatinib can be metabolized by Bacteroides stercoris. | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Imatinib can be metabolized by Bacteroides vulgatus. | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Imatinib can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.453; p = 0.028). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Anaerostipes sp.
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Imatinib can be metabolized by Anaerostipes sp. (log2FC = -0.405; p = 0.037). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [8] |
| Mcl-1 messenger RNA (MCL-1 mRNA) | Target Info | . | [5] | |
| Platelet-derived growth factor receptor (PDGFR) | Target Info | Inhibitor | [8] | |
| Tyrosine-protein kinase Kit (KIT) | Target Info | Inhibitor | [8] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006806) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687). | |||
| REF 4 | Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. | |||
| REF 5 | Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. | |||
| REF 6 | Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clin Transl Sci. 2020 Mar;13(2):238-259. | |||
| REF 7 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 8 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.